Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma

被引：5

作者：

Majem, M. ^{[1
]}

Felip, E. ^{[2
]}

Doger, B. ^{[3
]}

Akay, M. ^{[4
]}

Carcereny, E. ^{[5
]}

Clay, T. ^{[6
]}

Krebs, M. G. ^{[7
]}

Peguero, J. ^{[8
]}

Triebel, F. ^{[9
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain

[2] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain

[3] Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain

[4] Univ Coll London Hosp, Oncol Dept, London, England

[5] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol Badalona, Oncol Dept, Badalona, Spain

[6] St John God Subiaco Hosp, Oncol Dept, Perth, WA, Australia

[7] Christie NHS Fdn Trust, Div Canc Sci, Manchester, Lancs, England

[8] Oncol Consultants, Oncol Dept, Houston, TX USA

[9] Immutep SAS Immutep, Immunol, Orsay, France

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1580

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1266P

引用

页码：S818 / S818

页数：1

共 50 条

[1] A phase II study (TACTI-002) in first-line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
Felip, Enriqueta
Majem, Margarita
Doger, Bernard
Clay, Timothy Dudley
Carcereny, Enric
Bondarenko, Igor
Peguero, Julio Antonio
Cobo-Dols, Manuel
Forster, Martin
Ursol, Grygorii
Ledo, Gema Garcia
Vila, Laia
Krebs, Matthew
Iams, Wade Thomas
Mueller, Christian
Triebel, Frederic
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] A PHASE II STUDY (TACTI-002) OF EFTILAGIMOD ALPHA (A SOLUBLE LAG-3 PROTEIN) WITH PEMBROLIZUMAB IN PD-L1 UNSELECTED PATIENTS WITH METASTATIC NON-SMALL CELL LUNG(NSCLC) OR HEAD AND NECK CARCINOMA(HNSCC)
Krebs, Matthew
Majem, Margarita
Felip, Enriqueta
Forster, Martin
Doger, Bernard
Clay, Tim
Carcereny, Enric
Peguero, Julio
Horn, Leora
Bajaj, Pawan
Roxburgh, Patricia
Brignone, Chrystelle
Mueller, Christian
Triebel, Frederic
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A472 - A473
[3] Initial Results from a Phase II Study (TACTI-002) in Metastatic Non-Small Cell Lung or Head and Neck Carcinoma Patients Receiving Eftilagimod Alpha (Soluble Lag-3 Protein) and Pembrolizumab
Doger, Berhard
Majem, Margarita
Felip, Eriqueta
Carcereney, Enric
Clay, Tim
Triebel, Frederic
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 213 - 214
[4] Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.
Felip, Enriqueta
Doger, Bernard
Majem, Margarita
Carcereny, Enric
Krebs, Matthew
Peguero, Julio Antonio
Roxburgh, Patricia
Forster, Martin
Bajaj, Pawan
Clay, Timothy Dudley
Triebel, Frederic
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients
Forster, M.
Felip, E.
Doger, B.
Lopez Pousa, A.
Carcereny, E.
Bajaj, P.
Church, M.
Peguero, J.
Roxburgh, P.
Triebel, F.
ANNALS OF ONCOLOGY, 2020, 31 : S667 - S667
[6] Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.
Clay, Timothy Dudley
Majem, Margarita
Felip, Enriqueta
Doger, Bernard
Costa, Enric Carcereny
Forster, Martin
Krebs, Matthew
Peguero, Julio Antonio
Mueller, Christian
Triebel, Frederic
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC
Forster, M.
Krebs, M.
Majem, M.
Peguero, J.
Clay, T.
Felip, E.
Iams, W.
Roxburgh, P.
Doger, B.
Bajaj, P.
Kefas, J.
Scott, J. A.
Joaquin, A. Barba
Mueller, C.
Triebel, F.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S395 - S395
[8] Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab
Peguero, Julio
Felip, Enriqueta
Doger, Bernard
Majem, Margarita
Carcereny, Enric
Clay, Tim
Bajaj, Pawan
Krebs, Matthew
Triebel, Frederic
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[9] Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
Doger de Speville, Bernard
Felip, Enriqueta
Forster, Martin
Majem, Margarita
Bajaj, Pawan
Peguero, Julio Antonio
Carcereny, Enric
Krebs, Matthew G.
Mukherjee, Uma
Mueller, Christian
Triebel, Frederic
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] A PHASE II STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB IN PATIENTS UNSELECTED FOR PD-L1 EXPRESSION IN FIRST LINE METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Peguero, Julio
Triebel, Frederic
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A470 - A470

← 1 2 3 4 5 →